Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jun 14, 2023 9:22pm
176 Views
Post# 35497232

RE:RE:Shure hope they avoid another OO at these levels

RE:RE:Shure hope they avoid another OO at these levelsI would need to know quite a bit more before committing to additional investment and deciding on what was a reasonable price under whatever circumstances the company is actually in at the time. I would need to spend time with Christian to get answers to quite a few questions and would need to know what plan A is (if TH-1902 works) and plan B (if it doesn't), at a minimum. My hope is they can keep things together financially until such time as they know if they will be pursuing Plan A or Plan B. If they can't do that, it will not be a good situation. If they can, then they it should be a lot easier to pull off in a non-disastrous way. If Plan A come to fruition, obviously, a higher price on any offering would be justified withthe actual price determined bythe strength of the results. If instead, Plan B is unfortunatly needed, then we would all need a really good and believable budget to determine what price would be fair, but it is hard to see a ton of interest in the stock if all it offers is th two legacy drugs.

Also, I mentioned the financing OMER did where they sold future revenues of their drug at a discount to raise cash. It might be something THTX should consider if their confidence is high that TH-1902 is going to work. 
Wino115 wrote: Let's poll folks.  At what price and amount would you be ok with them taking down some ATM at?

Let's make these assumptions: Take down next Marathon round and pay off full convert. Hit EBITDA breakeven at FY end. 

How much and at what price is satisfactory to you?


<< Previous
Bullboard Posts
Next >>